Biomaterial Database

Case report: Marathon runner with severe autonomic failure. 2005

Emily M Garland, and Satish R Raj, and Nicholas Demartinis, and David Robertson

Autonomic Dysfunction Center, Vanderbilt University, Nashville, TN 37232, USA. david.robertson@vanderbilt.edu

UI	MeSH Term	Description	Entries
D004299	Dopamine beta-Hydroxylase		Dopamine beta-Monooxygenase,Dopamine beta Hydroxylase,Dopamine beta Monooxygenase,beta-Hydroxylase, Dopamine,beta-Monooxygenase, Dopamine
D005081	Exercise Therapy	A regimen or plan of physical activities designed and prescribed for specific therapeutic goals. Its purpose is to restore normal musculoskeletal function or to reduce pain caused by diseases or injuries.	Rehabilitation Exercise,Remedial Exercise,Therapy, Exercise,Exercise Therapies,Exercise, Rehabilitation,Exercise, Remedial,Exercises, Rehabilitation,Exercises, Remedial,Rehabilitation Exercises,Remedial Exercises,Therapies, Exercise
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328	Adult	A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available.	Adults
D000978	Antiparkinson Agents	Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.	Antiparkinson Drugs,Antiparkinsonian Agents,Antiparkinsonians,Agents, Antiparkinson,Agents, Antiparkinsonian,Drugs, Antiparkinson
D012420	Running	An activity in which the body is propelled by moving the legs rapidly. Running is performed at a moderate to rapid pace and should be differentiated from JOGGING, which is performed at a much slower pace.	Runnings
D012791	Shy-Drager Syndrome	A progressive neurodegenerative condition of the central and autonomic nervous systems characterized by atrophy of the preganglionic lateral horn neurons of the thoracic spinal cord. This disease is generally considered a clinical variant of MULTIPLE SYSTEM ATROPHY. Affected individuals present in the fifth or sixth decade with ORTHOSTASIS and bladder dysfunction; and later develop FECAL INCONTINENCE; anhidrosis; ATAXIA; IMPOTENCE; and alterations of tone suggestive of basal ganglia dysfunction. (From Adams et al., Principles of Neurology, 6th ed, p536)	Autonomic Failure, Progressive,Idiopathic Orthostatic Hypotension, Shy-Drager Type,Orthostatic Hypotension, Dysautonomic,Dysautonomia-Orthostatic Hypotension Syndrome,Syndrome, Dysautonomia-Orthostatic Hypotension,Autonomic Failures, Progressive,Dysautonomia Orthostatic Hypotension Syndrome,Dysautonomia-Orthostatic Hypotension Syndromes,Dysautonomic Orthostatic Hypotension,Dysautonomic Orthostatic Hypotensions,Failure, Progressive Autonomic,Failures, Progressive Autonomic,Hypotension Syndrome, Dysautonomia-Orthostatic,Hypotension Syndromes, Dysautonomia-Orthostatic,Hypotension, Dysautonomic Orthostatic,Hypotensions, Dysautonomic Orthostatic,Idiopathic Orthostatic Hypotension, Shy Drager Type,Orthostatic Hypotensions, Dysautonomic,Progressive Autonomic Failure,Progressive Autonomic Failures,Shy Drager Syndrome,Syndrome, Dysautonomia Orthostatic Hypotension,Syndrome, Shy-Drager,Syndromes, Dysautonomia-Orthostatic Hypotension
D015103	Droxidopa	A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION.	3,4-Dihydroxyphenylserine,3,4-threo-DOPS,DL-threo-3,4-Dihydroxyphenylserine,Droxidopa, (DL-Tyr)-Isomer,erythro-3,4-Dihydroxyphenylserine,threo-DOPS,3,4 Dihydroxyphenylserine,3,4 threo DOPS,DL threo 3,4 Dihydroxyphenylserine,erythro 3,4 Dihydroxyphenylserine,threo DOPS